ProfileGDS5678 / 1418926_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 88% 88% 87% 88% 82% 82% 85% 84% 91% 90% 90% 90% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8600888
GSM967853U87-EV human glioblastoma xenograft - Control 26.9288288
GSM967854U87-EV human glioblastoma xenograft - Control 36.9147488
GSM967855U87-EV human glioblastoma xenograft - Control 46.8627587
GSM967856U87-EV human glioblastoma xenograft - Control 56.9245188
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7323782
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8286682
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3202285
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1476384
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.3982591
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1802590
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.3581190
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3181990
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.4879891